Biological pathways and potential targets for prevention and therapy of chronic allograft nephropathy

BioMed Research International

Volumn 2014, Issue , 2014, Pages

  Shrestha, Badri Man ^a   Haylor, John ^a  

^a NORTHERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1 [5 CHLORO 2 [2 [4 (4 FLUOROBENZYL) 2 METHYL 1 PIPERAZINYL] 2 OXOETHOXY]PHENYL]UREA; ANGIOTENSIN RECEPTOR ANTAGONIST; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; CONNECTIVE TISSUE GROWTH FACTOR; DECORIN; ENDOTHELIN 1; GELATINASE A; GELATINASE B; IMATINIB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOSUPPRESSIVE AGENT; OSTEOGENIC PROTEIN 1; PIRFENIDONE; PLATELET DERIVED GROWTH FACTOR; PROCOLLAGEN PROLINE 2 OXOGLUTARATE 4 DIOXYGENASE; RANTES; RELAXIN; RETINOID; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; SCATTER FACTOR; SMAD PROTEIN; STROMELYSIN; TANOMASTAT; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN;

ARTERY DISEASE; BLOOD VESSEL INJURY; CAPILLARY BASEMENT MEMBRANE; CHRONIC ALLOGRAFT NEPHROPATHY; CLINICAL PATHWAY; ELECTRON MICROSCOPY; FIBROGENESIS; FIBROSIS; GLOMERULOPATHY; GLOMERULOSCLEROSIS; GLOMERULUS CAPILLARY; HUMAN; IMMUNOPATHOGENESIS; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY ALLOGRAFT; KIDNEY GRAFT REJECTION; KIDNEY ISCHEMIA; KIDNEY TRANSPLANTATION; KIDNEY TUBULE BASEMENT MEMBRANE; META ANALYSIS (TOPIC); NONHUMAN; OXIDATIVE STRESS; PATIENT CARE; PATIENT RISK; PROTEIN TARGETING; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK ASSESSMENT; RISK FACTOR; SYSTEMATIC REVIEW; TISSUE INJURY; VASCULAR ENDOTHELIUM; ADVERSE EFFECTS; ALLOGRAFT; CHRONIC DISEASE; KIDNEY DISEASES; PATHOLOGY; SIGNAL TRANSDUCTION;

ALLOGRAFTS; CHRONIC DISEASE; HUMANS; KIDNEY DISEASES; KIDNEY TRANSPLANTATION; RISK FACTORS; SIGNAL TRANSDUCTION;

EID: 84902135340     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2014/482438     Document Type: Review

References (128)

1. Shrestha A., Shrestha A., Basarab-Horwath C., McKane W., Shrestha B., Raftery A., Quality of life following live donor renal transplantation: a single centre experience. Annals of Transplantation 2010 15 2 5 10 2-s2.0-77954653142
2. Heemann U., Lutz J., Pathophysiology and treatment options of chronic renal allograft damage. Nephrology, Dialysis, Transplantation 2013 28 10 2438 2446
3. Paul L. C., Chronic allograft nephropathy: an update. Kidney International 1999 56 3 783 793 2-s2.0-0032844172 10.1046/j.1523-1755.1999. 00611.x (Pubitemid 29411708)
4. Cornell L. D., Colvin R. B., Chronic allograft nephropathy. Current Opinion in Nephrology and Hypertension 2005 14 3 229 234 2-s2.0-18844368491 (Pubitemid 40685634)
5. Haas M., Chronic allograft nephropathy or interstitial fibrosis and tubular atrophy: what is in a name? Current Opinion in Nephrology and Hypertension 2014 23 3 245 250
6. Schweitzer E. J., Matas A. J., Gillingham K. J., Payne W. D., Gores P. F., Dunn D. L., Sutherland D. E. R., Najarian J. S., Causes of renal allograft loss: progress in the 1980s, challenges for the 1990s. Annals of Surgery 1991 214 6 679 688 2-s2.0-0026335235
7. Sijpkens Y. W. J., Doxiadis I. I. N., van Kemenade F. J., Zwinderman A. H., de Fijter J. W., Claas F. H. J., Bruijn J. A., Paul L. C., Chronic rejection with or without transplant vasculopathy. Clinical Transplantation 2003 17 3 163 170 2-s2.0-0012952160 10.1034/j.1399-0012.2003.00039.x (Pubitemid 36748460)
8. Naesens M., Kuypers D. R. J., De Vusser K., Vanrenterghem Y., Evenepoel P., Claes K., Bammens B., Meijers B., Lerut E., Chronic histological damage in early indication biopsies is an independent risk factor for late renal allograft failure. American Journal of Transplantation 2013 13 1 86 99 2-s2.0-84871716526 10.1111/j.1600-6143.2012.04304.x
9. Sigdel T. K., Li L., Tran T. Q., Khatri P., Naesens M., Sansanwal P., Dai H., Hsieh S.-C., Sarwal M. M., Non-HLA antibodies to immunogenic epitopes predict the evolution of chronic renal allograft injury. Journal of the American Society of Nephrology 2012 23 4 750 763 2-s2.0-84859858471 10.1681/ASN. 2011060596
10. Pascual J., Pérez-Sáez M. J., Mir M., Crespo M., Chronic renal allograft injury: early detection, accurate diagnosis and management. Transplantation Reviews 2012 26 4 280 290 2-s2.0-84866755069 10.1016/j.trre.2012.07.002
11. Paul L. C., Pathogenesis of chronic allograft nephropathy. Current Opinion in Nephrology and Hypertension 1998 7 6 635 637 2-s2.0-0031773780 10.1097/00041552-199811000-00001 (Pubitemid 28551663)
12. Maryniak R. K., First M. R., Weiss M. A., Transplant glomerulopathy: evolution of morphologically distinct changes. Kidney International 1985 27 5 799 806 2-s2.0-0021854866 (Pubitemid 15064642)
13. Brenner B. M., Lawler E. V., Mackenzie H. S., The hyperfiltration theory: a paradigm shift in nephrology. Kidney International 1996 49 6 1774 1777 2-s2.0-0029902698 (Pubitemid 26186610)
14. Brenner B. M., Meyer T. W., Hostetter T. H., Dietary protein intake and the progressive nature of kidney disease: the role of hemodynamically mediated glomerular injury in the pathogenesis of progressive glomerular sclerosis in aging, renal ablation, and intrinsic renal disease. The New England Journal of Medicine 1982 307 11 652 659 2-s2.0-0020324688 (Pubitemid 12049914)
15. Weir M. R., Wali R. K., Minimizing the risk of chronic allograft nephropathy. Transplantation 2009 87 8 S14 S18 2-s2.0-65549162647
16. Lal S. M., Luger A. M., Saha L. K., Ross G. Jr., De novo membranous glomerulopathy in renal allografts with unusual histology. International Journal of Artificial Organs 1995 18 2 78 80 2-s2.0-0029040135
17. Tsay D. Y., Lian J. D., Shu K. H., Lu Y. S., Chan L. P., Chang C. H., Yang C. R., Glomerular diseases in human renal allograft. Journal of the Formosan Medical Association 1991 90 11 1038 1043 2-s2.0-0026248495
18. Ortiz F., Paavonen T., Törnroth T., Koskinen P., Finne P., Salmela K., Kyllönen L., Grönhagen-Riska C., Honkanen E., Predictors of renal allograft histologic damage progression. Journal of the American Society of Nephrology 2005 16 3 817 824 2-s2.0-20544442781 10.1681/ASN.2004060475 (Pubitemid 41725119)
19. Boor P., Ostendorf T., Floege J., Renal fibrosis: novel insights into mechanisms and therapeutic targets. Nature Reviews Nephrology 2010 6 11 643 656 2-s2.0-78049369136 10.1038/nrneph.2010.120
20. Ivanyi B., Kemeny E., Szederkenyi E., Marofka F., Szenohradszky P., The value of electron microscopy in the diagnosis of chronic renal allograft rejection. Modern Pathology 2001 14 12 1200 1208 2-s2.0-0035217786 10.1038/modpathol.3880461 (Pubitemid 33151161)
21. Massy Z. A., Guijarro C., Wiederkehr M. R., Ma J. Z., Kasiske B. L., Chronic renal allograft rejection: immunologic and nonimmunologic risk factors. Kidney International 1996 49 2 518 524 2-s2.0-0030065639 (Pubitemid 26051834)
22. Halloran P. F., Melk A., Barth C., Rethinking chronic allograft nephropathy: the concept of accelerated senescence. Journal of the American Society of Nephrology 1999 10 1 167 181 2-s2.0-0032946290 (Pubitemid 29034957)
23. Nankivell B. J., Borrows R. J., Fung C. L.-S., O'Connell P. J., Allen R. D. M., Chapman J. R., The natural history of chronic allograft nephropathy. The New England Journal of Medicine 2003 349 24 2326 2333 2-s2.0-0344666767 10.1056/NEJMoa020009 (Pubitemid 37509740)
24. Djamali A., Oxidative stress as a common pathway to chronic tubulointerstitial injury in kidney allografts. American Journal of Physiology 2007 293 2 F445 F455 2-s2.0-34548419397 10.1152/ajprenal.00037.2007 (Pubitemid 47358116)
25. Benigni A., Bruzzi I., Mister M., Azzollini N., Gaspari F., Perico N., Gotti E., Bertani T., Remuzzi G., Nature and mediators of renal lesions in kidney transplant patients given cyclosporine for more than one year. Kidney International 1999 55 2 674 685 2-s2.0-0032961456 10.1046/j.1523-1755.1999. 00288.x (Pubitemid 29082894)
26. Hertig A., Verine J., Mougenot B., Jouanneau C., Ouali N., Sebe P., Glotz D., Ancel P.-Y., Rondeau E., Xu-Dubois Y.-C., Risk factors for early epithelial to mesenchymal transition in renal grafts. American Journal of Transplantation 2006 6 12 2937 2946 2-s2.0-33751184559 10.1111/j.1600-6143.2006.01559.x
27. Djamali A., Reese S., Yracheta J., Oberley T., Hullett D., Becker B., Epithelial-to-mesenchymal transition and oxidative stress in chronic allograft nephropathy. American Journal of Transplantation 2005 5 3 500 509 2-s2.0-14644442299 10.1111/j.1600-6143.2004.00713.x (Pubitemid 40313341)
28. Melk A., Senescence of renal cells: molecular basis and clinical implications. Nephrology Dialysis Transplantation 2003 18 12 2474 2478 2-s2.0-0344034290 10.1093/ndt/gfg322 (Pubitemid 37483777)
29. Siekierka-Harreis M., Kuhr N., Willers R., Ivens K., Grabensee B., Mondry A., Loh M. C. S., Rump L. C., Blume C., Impact of genetic polymorphisms of the renin-angiotensin system and of non-genetic factors on kidney transplant function-a single-center experience. Clinical Transplantation 2009 23 5 606 615 2-s2.0-70350158809 10.1111/j.1399-0012.2009.01033.x
30. Wilczynska J., Pfeil U., Zakrzewicz A., Dietrich H., Körner C., Hecker A., Wessler I., Padberg W., Kummer W., Grau V., Acetylcholine and chronic vasculopathy in rat renal allografts. Transplantation 2011 91 3 263 270 2-s2.0-79951516338 10.1097/TP.0b013e3182038654
31. Abo-Zenah H., Katsoudas S., De Takats D., Shortland J., Wild G., Brown C. B., El Nahas A. M., Early progressive interstitial fibrosis in human renal allografts. Clinical Nephrology 2002 57 1 9 18 2-s2.0-0036145249 (Pubitemid 34071621)
32. Kuypers D. R. J., Chapman J. R., O'Connell P. J., Allen R. D. M., Nankivell B. J., Predictors of renal transplant histology at three months. Transplantation 1999 67 9 1222 1230 2-s2.0-0033562727 10.1097/00007890- 199905150-00005 (Pubitemid 29239472)
33. Mannon R. B., Therapeutic targets in the treatment of allograft fibrosis. American Journal of Transplantation 2006 6 5 867 875 2-s2.0-33745238684 10.1111/j.1600-6143.2006.01261.x (Pubitemid 44356636)
34. Amer H., Griffin M. D., Modulating kidney transplant interstitial fibrosis and tubular atrophy: is the RAAS an important target? Kidney International 2014 85 2 240 243
35. Heilman R. L., Devarapalli Y., Chakkera H. A., Mekeel K. L., Moss A. A., Mulligan D. C., Mazur M. J., Hamawi K., Williams J. W., Reddy K. S., Impact of subclinical inflammation on the development of interstitial fibrosis and tubular atrophy in kidney transplant recipients. American Journal of Transplantation 2010 10 3 563 570 2-s2.0-76949097789 10.1111/j.1600-6143.2009.02966.x
36. Böttinger E. P., TGF- β in renal injury and disease. Seminars in Nephrology 2007 27 3 309 320 2-s2.0-34249052234 10.1016/j.semnephrol.2007.02. 009 (Pubitemid 46802921)
37. Tyler J. R., Robertson H., Booth T. A., Burt A. D., Kirby J. A., Chronic allograft nephropathy: intraepithelial signals generated by transforming growth factor- β and bone morphogenetic protein-7. American Journal of Transplantation 2006 6 6 1367 1376 2-s2.0-33745819270 10.1111/j.1600-6143.2006. 01339.x (Pubitemid 44030319)
38. Zavadil J., Böttinger E. P., TGF- β and epithelial-to- mesenchymal transitions. Oncogene 2005 24 37 5764 5774 2-s2.0-24644487312 10.1038/sj.onc.1208927 (Pubitemid 43086136)
39. Park S., DiMaio T. A., Liu W., Wang S., Sorenson C. M., Sheibani N., Endoglin regulates the activation and quiescence of endothelium by participating in canonical and non-canonical TGF- β signaling pathways. Journal of Cell Science 2013 126 6 1392 1405 2-s2.0-84877890780 10.1242/jcs.117275
40. Fan J.-M., Yee-Yung N. G., Hill P. A., Nikolic-Paterson D. J., Mu W., Atkins R. C., Lan H. Y., Transforming growth factor- β regulates tubular epithelial-myofibroblast transdifferentiation in vitro. Kidney International 1999 56 4 1455 1467 2-s2.0-0032842887 10.1046/j.1523-1755.1999.00656.x (Pubitemid 29451252)
41. Hayashida T., Decaestecker M., Schnaper H. W., Cross-talk between ERK MAP kinase and Smad signaling pathways enhances TGF-beta-dependent responses in human mesangial cells. The FASEB Journal 2003 17 11 1576 1578 2-s2.0-0042704734
42. Strutz F., Zeisberg M., Ziyadeh F. N., Yang C.-Q., Kalluri R., Müller G. A., Neilson E. G., Renziehausen A., Sisic Z., Role of basic fibroblast growth factor-2 in epithelial-mesenchymal transformation. Kidney International 2002 61 5 1714 1728 2-s2.0-0036233040 10.1046/j.1523-1755.2002. 00333.x (Pubitemid 34437925)
43. Pawluczyk I. Z. A., Harris K. P. G., Macrophages promote prosclerotic responses in cultured rat mesangial cells: a mechanism for the initiation of glomerulosclerosis. Journal of the American Society of Nephrology 1997 8 10 1525 1536 2-s2.0-0030720866 (Pubitemid 27496470)
44. Kriz W., Kretzler M., Nagata M., Provoost A. P., Shirato I., Uiker S., Sakai T., Lemley K. V., A frequent pathway to glomerulosclerosis: deterioration of tuft architecture-podocyte damage-segmental sclerosis. Kidney and Blood Pressure Research 1996 19 5 245 253 2-s2.0-0029946426 (Pubitemid 26395311)
45. Ljungquist A., The intrarenal arterial pattern in the normal and deseased human kidney. Acta Medica Scandinavica 1963 174 supplement 401 5 34
46. Kang D.-H., Kanellis J., Hugo C., Truong L., Anderson S., Kerjaschki D., Schreiner G. F., Johnson R. J., Role of the microvascular endothelium in progressive renal disease. Journal of the American Society of Nephrology 2002 13 3 806 816 2-s2.0-0036191166 (Pubitemid 34183950)
47. Norman J. T., Clark I. M., Garcia P. L., Hypoxia promotes fibrogenesis in human renal fibroblasts. Kidney International 2000 58 6 2351 2366 2-s2.0-0033662026 10.1046/j.1523-1755.2000.00419.x
48. Renders L., Heemann U., Chronic renal allograft damage after transplantation: what are the reasons, what can we do? Current Opinion in Organ Transplantation 2012 17 6 634 639 2-s2.0-84870255948 10.1097/MOT. 0b013e32835a4bfa
49. Djamali A., Samaniego M., Fibrogenesis in kidney transplantation: potential targets for prevention and therapy. Transplantation 2009 88 10 1149 1156 2-s2.0-73849095809 10.1097/TP.0b013e3181bcccea
50. Song E., Zou H., Yao Y., Proudfoot A., Antus B., Lui S., Jens L., Heemann U., Early application of Met-RANTES ameliorates chronic allograft nephropathy. Kidney International 2002 61 2 676 685 2-s2.0-0036158099 10.1046/j.1523-1755. 2002.00148.x (Pubitemid 34102611)
51. Bedke J., Kiss E., Schaefer L., Behnes C.-L., Bonrouhi M., Gretz N., Horuk R., Diedrichs-Moehring M., Wildner G., Nelson P. J., Gröne H. J., Beneficial effects of CCR1 blockade on the progression of chronic renal allograft damage. American Journal of Transplantation 2007 7 3 527 537 2-s2.0-33847701747 10.1111/j.1600-6143.2006.01654.x (Pubitemid 46376438)
52. Land W., Schneeberger H., Schleibner S., Illner W.-D., Abendroth D., Rutili G., Arfors K. E., Messmer K., The beneficial effect of human recombinant superoxide dismutase on acute and chronic rejection events in recipients of cadaveric renal transplants. Transplantation 1994 57 2 211 217 2-s2.0-0027979555 (Pubitemid 24048587)
53. Pollak R., Andrisevic J. H., Maddux M. S., Gruber S. A., Paller M. S., A randomized double-blind trial of the use of human recombinant superoxide dismutase in renal transplantation. Transplantation 1993 55 1 57 60 2-s2.0-0027505597 (Pubitemid 23033945)
54. Nickenig G., Harrison D. G., The AT1-type angiotensin receptor in oxidative stress and atherogenesis: part I: oxidative stress and atherogenesis. Circulation 2002 105 3 393 396 2-s2.0-0037154324 10.1161/hc0302.102618 (Pubitemid 34106191)
55. Chabrashvili T., Kitiyakara C., Blau J., Karber A., Aslam S., Welch W. J., Wilcox C. S., Effects of ANG II type 1 and 2 receptors on oxidative stress, renal NADPH oxidase, and SOD expression. American Journal of Physiology 2003 285 1 R117 R124 2-s2.0-0037974569 (Pubitemid 36736508)
56. Bhaskaran M., Reddy K., Radhakrishanan N., Franki N., Ding G., Singhal P. C., Angiotensin II induces apoptosis in renal proximal tubular cells. American Journal of Physiology 2003 284 5 F955 F965 2-s2.0-0037404859 (Pubitemid 36443580)
57. Burnier M., Zanchi A., Blockade of the renin-angiotensin-aldosterone system: a key therapeutic strategy to reduce renal and cardiovascular events in patients with diabetes. Journal of Hypertension 2006 24 1 11 25 2-s2.0-29144521901 (Pubitemid 41818080)
58. Heinze G., Mitterbauer C., Regele H., Kramar R., Winkelmayer W. C., Curhan G. C., Oberbauer R., Angiotensin-converting enzyme inhibitor or angiotensin II type 1 receptor antagonist therapy is associated with prolonged patient and graft survival after renal transplantation. Journal of the American Society of Nephrology 2006 17 3 889 899 2-s2.0-33645451066 10.1681/ASN. 2005090955
59. Hiremath S., Fergusson D., Doucette S., Mulay A. V., Knoll G. A., Renin angiotensin system blockade in kidney transplantation: a systematic review of the evidence. American Journal of Transplantation 2007 7 10 2350 2360 2-s2.0-34548301629 10.1111/j.1600-6143.2007.01928.x (Pubitemid 47347851)
60. Knoll G. A., Cantarovitch M., Cole E., Gill J., Gourishankar S., Holland D., Kiberd B., Muirhead N., Prasad R., Tibbles L. A., Treleaven D., Fergusson D., The Canadian ACE-inhibitor trial to improve renal outcomes and patient survival in kidney transplantation-study design. Nephrology Dialysis Transplantation 2008 23 1 354 358 2-s2.0-44449094269 10.1093/ndt/gfm574 (Pubitemid 351767383)
61. Mannon R. B., Kopp J. B., Ruiz P., Griffiths R., Bustos M., Platt J. L., Klotman P. E., Coffman T. M., Chronic rejection of mouse kidney allografts. Kidney International 1999 55 5 1935 1944 2-s2.0-0032894729 10.1046/j.1523-1755. 1999.00423.x (Pubitemid 29197982)
62. Khanna A. K., Cairns V. R., Becker C. G., Hosenpud J. D., Transforming growth factor (TGF)- β mimics and anti-TGF- β antibody abrogates the in vivo effects of cyclosporine demonstration of a direct role of TGF- β in immunosuppression and nephrotoxicity of cyclosporine. Transplantation 1999 67 6 882 889 2-s2.0-0033608710 (Pubitemid 29169135)
63. Shull M. M., Ormsby I., Kier A. B., Pawlowski S., Diebold R. J., Yin M., Allen R., Sidman C., Proetzel G., Calvin D., Annunziata N., Doetschman T., Targeted disruption of the mouse transforming growth factor- β 1 gene results in multifocal inflammatory disease. Nature 1992 359 6397 693 699 2-s2.0-0026799402 10.1038/359693a0
64. Eikmans M., Sijpkens Y. W. J., Baelde H. J., De Heer E., Paul L. C., Bruijn J. A., High transforming growth factor- β and extracellular matrix mRNA response in renal allografts during early acute rejection is associated with absence of chronic rejection. Transplantation 2002 73 4 573 579 2-s2.0-0037181103 (Pubitemid 34193618)
65. Shihab F. S., Bennett W. M., Yi H., Andoh T. F., Pirfenidone treatment decreases transforming growth factor- β 1 and matrix proteins and ameliorates fibrosis in chronic cyclosporine nephrotoxicity. American Journal of Transplantation 2002 2 2 111 119 2-s2.0-0347996179 10.1034/j.1600-6143.2002. 020201.x (Pubitemid 36306789)
66. Shihab F. S., Bennett W. M., Yi H., Andoh T. F., Effect of pirfenidone on apoptosis-regulatory genes in chronic cyclosporine nephrotoxicity. Transplantation 2005 79 4 419 426 2-s2.0-14044262258 10.1097/01.TP.0000151721. 99418.48 (Pubitemid 40280173)
67. Cho M. E., Smith D. C., Branton M. H., Penzak S. R., Kopp J. B., Pirfenidone slows renal function decline in patients with focal segmental glomerulosclerosis. Clinical Journal of the American Society of Nephrology 2007 2 5 906 913 2-s2.0-34548834734 10.2215/CJN.01050207
68. Heeg M. H. J., Koziolek M. J., Vasko R., Schaefer L., Sharma K., Müller G. A., Strutz F., The antifibrotic effects of relaxin in human renal fibroblasts are mediated in part by inhibition of the Smad2 pathway. Kidney International 2005 68 1 96 109 2-s2.0-24944542890 10.1111/j.1523-1755.2005. 00384.x (Pubitemid 43181367)
69. Samuel C. S., Zhao C., Bathgate R. A. D., Du X.-J., Summers R. J., Amento E. P., Walker L. L., McBurnie M., Zhao L., Tregear G. W., The relaxin gene-knockout mouse: a model of progressive fibrosis. Annals of the New York Academy of Sciences 2005 1041 173 181 2-s2.0-23644459331 10.1196/annals.1282.025 (Pubitemid 41132243)
70. Garber S. L., Mirochnik Y., Brecklin C. S., Unemori E. N., Singh A. K., Slobodskoy L., Grove B. H., Arruda J. A. L., Dunea G., Relaxin decreases renal interstitial fibrosis and slows progression of renal disease. Kidney International 2001 59 3 876 882 2-s2.0-0035096195 10.1046/j.1523-1755.2001. 059003876.x (Pubitemid 32206850)
71. Schaefer L., Macakova K., Raslik I., Micegova M., Gröne H.-J., Schönherr E., Robenek H., Echtermeyer F. G., Grässel S., Bruckner P., Schaefer R. M., Iozzo R. V., Kresse H., Absence of decorin adversely influences tubulointerstitial fibrosis of the obstructed kidney by enhanced apoptosis and increased inflammatory reaction. American Journal of Pathology 2002 160 3 1181 1191 2-s2.0-0036118493 (Pubitemid 34224603)
72. Border W. A., Noble N. A., Yamamoto T., Harper J. R., Yamaguchi Y., Pierschbacher M. D., Ruoslahti E., Natural inhibitor of transforming growth factor- β protects against scarring in experimental kidney disease. Nature 1992 360 6402 361 364 2-s2.0-0026676859 10.1038/360361a0 (Pubitemid 23000677)
73. Nakatani T., Tanabe S., Han Y.-S., Kayo S., Yoshimi N., Hai E., Shirai N., Ikura Y., Ohsawa M., Ueda M., Enhanced expression of endothelin-A receptor in human transplant renal arteriosclerosis. International Journal of Molecular Medicine 2003 11 2 153 156 2-s2.0-0042202192
74. Inman S. R., Plott W. K., Pomilee R. A., Antonelli J. A., Lewis R. M., Endothelin-receptor blockade mitigates the adverse effect of preretrieval warm ischemia on posttransplantation renal function in rats. Transplantation 2003 75 10 1655 1659 2-s2.0-0037674658 10.1097/01.TP.0000063127.02261.E4 (Pubitemid 36629145)
75. Tikkanen J. M., Koskinena P. K., Lemström K. B., Role of endogenous endothelin-1 in transplant obliterative airway disease in the rat. American Journal of Transplantation 2004 4 5 713 720 2-s2.0-2442545702 10.1111/j.1600-6143.2004.00414.x (Pubitemid 38637568)
76. Zeisberg M., Hanai J.-I., Sugimoto H., Mammoto T., Charytan D., Strutz F., Kalluri R., BMP-7 counteracts TGF- β 1-induced epithelial-to- mesenchymal transition and reverses chronic renal injury. Nature Medicine 2003 9 7 964 968 2-s2.0-0038717407 10.1038/nm888 (Pubitemid 36889942)
77. Grotendorst G. R., Connective tissue growth factor: a mediator of TGf- β action on fibroblasts. Cytokine and Growth Factor Reviews 1997 8 3 171 179 2-s2.0-0031225015 10.1016/S1359-6101(97)00010-5 (Pubitemid 28077925)
78. Nguyen T. Q., Roestenberg P., Van Nieuwenhoven F. A., Bovenschen N., Li Z., Xu L., Oliver N., Aten J., Joles J. A., Vial C., Brandan E., Lyons K. M., Goldschmeding R., CTGF inhibits BMP-7 signaling in diabetic nephropathy. Journal of the American Society of Nephrology 2008 19 11 2098 2107 2-s2.0-55749104230 10.1681/ASN.2007111261
79. Cheng O., Thuillier R., Sampson E., Schultz G., Ruiz P., Zhang X., Yuen P. S. T., Mannon R. B., Connective tissue growth factor is a biomarker and mediator of kidney allograft fibrosis. American Journal of Transplantation 2006 6 10 2292 2306 2-s2.0-33748486969 10.1111/j.1600-6143.2006.01493.x (Pubitemid 44359414)
80. Luo G. H., Lu Y. P., Song J., Yang L., Shi Y. J., Li Y. P., Inhibition of connective tissue growth factor by small interfering RNA prevents renal fibrosis in rats undergoing chronic allograft nephropathy. Transplantation Proceedings 2008 40 7 2365 2369 2-s2.0-51249090127 10.1016/j.transproceed.2008. 07.100
81. Wakino S., Kanda T., Hayashi K., Rho/Rho kinase as a potential target for the treatment of renal disease. Drug News and Perspectives 2005 18 10 639 643 2-s2.0-33645063200 10.1358/dnp.2005.18.10.959578
82. Sato M., Muragaki Y., Saika S., Roberts A. B., Ooshima A., Targeted disruption of TGF- β 1/Smad3 signaling protects against renal tubulointerstitial fibrosis induced by unilateral ureteral obstruction. Journal of Clinical Investigation 2003 112 10 1486 1494 2-s2.0-0346727324 10.1172/JCI200319270 (Pubitemid 38056275)
83. Nagatoya K., Moriyama T., Kawada N., Takeji M., Oseto S., Murozono T., Ando A., Imai E., Hori M., Y-27632 prevents tubulointerstitial fibrosis in mouse kidneys with unilateral ureteral obstruction. Kidney International 2002 61 5 1684 1695 2-s2.0-0036236193 10.1046/j.1523-1755.2002.00328.x (Pubitemid 34437922)
84. Ishimaru K., Ueno H., Kagitani S., Takabayashi D., Takata M., Inoue H., Fasudil attenuates myocardial fibrosis in association with inhibition of monocyte/macrophage infiltration in the heart of DOCA/salt hypertensive rats. Journal of Cardiovascular Pharmacology 2007 50 2 187 194 2-s2.0-34547945446 10.1097/FJC.0b013e318064f150 (Pubitemid 47267744)
85. Nakagawa T., Uncoupling of the VEGF-endothelial nitric oxide axis in diabetic nephropathy: an explanation for the paradoxical effects of VEGF in renal disease. American Journal of Physiology 2007 292 6 F1665 F1672 2-s2.0-34447625374 10.1152/ajprenal.00495.2006 (Pubitemid 47105355)
86. Özdemir B. H., Özdemir F. N., Haberal N., Emiroglu R., Demirhan B., Haberal M., Vascular endothelial growth factor expression and cyclosporine toxicity in renal allograft rejection. American Journal of Transplantation 2005 5 4 766 774 2-s2.0-16244410452 10.1111/j.1600-6143.2005.00772.x (Pubitemid 40461286)
87. Mizuno S., Matsumoto K., Nakamura T., HGF as a renotrophic and anti-fibrotic regulator in chronic renal disease. Frontiers in Bioscience 2008 13 18 7072 7086 2-s2.0-52049123764 10.2741/3211
88. Liu Y., Hepatocyte growth factor in kidney fibrosis: therapeutic potential and mechanisms of action. American Journal of Physiology 2004 287 1 -F16 2-s2.0-2942635909 10.1152/ajprenal.00451.2003 (Pubitemid 38780577)
89. Azuma H., Takahara S., Matsumoto K., Ichimaru N., Wang J. D., Moriyama T., Waaga A.-M., Kitamura M., Otsuki Y., Okuyama A., Katsuoka Y., Chandraker A., Sayegh M. H., Nakamura T., Hepatocyte growth factor prevents the development of chronic allograft nephropathy in rats. Journal of the American Society of Nephrology 2001 12 6 1280 1292 2-s2.0-0035005796 (Pubitemid 32472643)
90. Herrero-Fresneda I., Torras J., Franquesa M., Vidal A., Cruzado J. M., Lloberas N., Fillat C., Grinyó J. M., HGF gene therapy attenuates renal allograft scarring by preventing the profibrotic inflammatory-induced mechanisms. Kidney International 2006 70 2 265 274 2-s2.0-33746154515 10.1038/sj.ki.5001510 (Pubitemid 44086576)
91. Benvenuti S., Comoglio P. M., The MET receptor tyrosine kinase in invasion and metastasis. Journal of Cellular Physiology 2007 213 2 316 325 2-s2.0-34848855124 10.1002/jcp.21183 (Pubitemid 47509708)
92. Pihlajaniemi T., Myllyla R., Kivirikko K. I., Prolyl 4-hydroxylase and its role in collagen synthesis. Journal of Hepatology 1991 13 3 S2 S7 2-s2.0-0026006381
93. Franceschini N., Cheng O., Zhang X., Ruiz P., Mannon R. B., Inhibition of prolyl-4-hydroxylase ameliorates chronic rejection of mouse kidney allografts. American Journal of Transplantation 2003 3 4 396 402 2-s2.0-0037652301 10.1034/j.1600-6143.2003.00081.x (Pubitemid 36560090)
94. Inkinen K. A., Soots A. P., Krogerus L. A., Lautenschlager I. T., Ahonen J. P., Fibrosis and matrix metalloproteinases in rat renal allografts. Transplant International 2005 18 5 506 512 2-s2.0-23844520998 10.1111/j.1432-2277.2004.00053.x (Pubitemid 41726851)
95. Lutz J., Yao Y., Song E., Antus B., Hamar P., Liu S., Heemann U., Inhibition of matrix metalloproteinase during chronic allograft nephropathy in rats. Transplantation 2005 79 6 655 661 2-s2.0-16244399175 10.1097/01.TP. 0000151644.85832.B5 (Pubitemid 40463171)
96. Kreutz M., Fritsche J., Ackermann U., Krause S. W., Andreesen R., Retinoic acid inhibits monocyte to macrophage survival and differentiation. Blood 1998 91 12 4796 4802 2-s2.0-0031811701 (Pubitemid 28270331)
97. Adams J., Kiss E., Arroyo A. B. V., Bonrouhi M., Sun Q., Li Z., Gretz N., Schnitger A., Zouboulis C. C., Wiesel M., Wagner J., Nelson P. J., Gröne H.-J., 13-cis retinoic acid inhibits development and progression of chronic allograft nephropathy. American Journal of Pathology 2005 167 1 285 298 2-s2.0-21244473728 (Pubitemid 40884789)
98. Heldin C.-H., Eriksson U., Östman A., New members of the platelet-derived growth factor family of mitogens. Archives of Biochemistry and Biophysics 2002 398 2 284 290 2-s2.0-0037085234 10.1006/abbi.2001.2707 (Pubitemid 34848597)
99. Eitner F., Ostendorf T., Kretzler M., Cohen C. D., Eriksson U., Gröne H.-J., Floege J., PDGF-C expression in the developing and normal adult human kidney and in glomerular diseases. Journal of the American Society of Nephrology 2003 14 5 1145 1153 2-s2.0-0037406877 10.1097/01.ASN.0000062964. 75006.A8 (Pubitemid 36514657)
100. Iida H., Seifert R., Alpers C. E., Gronwald R. G. K., Phillips P. E., Pritzl P., Gordon K., Gown A. M., Ross R., Bowen-Pope D. F., Johnson R. J., Platelet-derived growth factor (PDGF) and PDGF receptor are induced in mesangial proliferative nephritis in the rat. Proceedings of the National Academy of Sciences of the United States of America 1991 88 15 6560 6564 2-s2.0-0026000337 10.1073/pnas.88.15.6560 (Pubitemid 21914987)
101. Matsuda M., Shikata K., Makino H., Sugimoto H., Ota K., Akiyama K., Hirata K., Ota Z., Gene expression of PDGF and PDGF receptor in various forms of glomerulonephritis. American Journal of Nephrology 1997 17 1 25 31 2-s2.0-0031040349 (Pubitemid 27062801)
102. Liu G., Changsirikulchai S., Hudkins K. L., Banas M. C., Kowalewska J., Yang X., Wietecha T. A., Volpone J., Gilbertson D. G., Alpers C. E., Identification of platelet-derived growth factor D in human chronic allograft nephropathy. Human Pathology 2008 39 3 393 402 2-s2.0-39049102406 10.1016/j.humpath.2007.07.008
103. Savikko J., Taskinen E., Von Willebrand E., Chronic allograft nephropathy is prevented by inhibition of platelet-derived growth factor receptor: tyrosine kinase inhibitors as a potential therapy. Transplantation 2003 75 8 1147 1153 2-s2.0-0037469034 10.1097/01.TP.0000062836.93496.CE (Pubitemid 36513012)
104. Rintala J. M., Savikko J., Rintala S. E., Von Willebrand E., FK778 ameliorates post-transplant expression of fibrogenic growth factors and development of chronic rejection changes in rat kidney allografts. Nephrology Dialysis Transplantation 2008 23 11 3446 3455 2-s2.0-54149098616 10.1093/ndt/gfn340
105. Gómez-Garre D., Largo R., Tejera N., Fortes J., Manzarbeitia F., Egido J., Activation of NF- B in tubular epithelial cells of rats with intense proteinuria role of angiotensin II and endothelin-1. Hypertension 2001 37 4 1171 1178 2-s2.0-0034744613 (Pubitemid 32304021)
106. Sakai N., Wada T., Furuichi K., Iwata Y., Yoshimoto K., Kitagawa K., Kokubo S., Kobayashi M., Hara A., Yamahana J., Okumura T., Takasawa K., Takeda S.-I., Yoshimura M., Kida H., Yokoyama H., Involvement of extracellular signal-regulated kinase and p38 in human diabetic nephropathy. American Journal of Kidney Diseases 2005 45 1 54 65 2-s2.0-19944396117 10.1053/j.ajkd.2004.08.039 (Pubitemid 40038045)
107. Tamada S., Nakatani T., Asai T., Tashiro K., Komiya T., Sumi T., Okamura M., Kim S., Iwao H., Kishimoto T., Yamanaka S., Miura K., Inhibition of nuclear factor- B activation by pyrrolidine dithiocarbamate prevents chronic FK506 nephropathy. Kidney International 2003 63 1 306 314 2-s2.0-6444245024 10.1046/j.1523-1755.2003.00714.x (Pubitemid 35463935)
108. Yamamoto Y., Gaynor R. B., Therapeutic potential of inhibition of the NF- B pathway in the treatment of inflammation and cancer. Journal of Clinical Investigation 2001 107 2 135 142 2-s2.0-0035139792 (Pubitemid 32096826)
109. Tashiro K., Tamada S., Kuwabara N., Komiya T., Takekida K., Asai T., Iwao H., Sugimura K., Matsumura Y., Takaoka M., Nakatani T., Miura K., Attenuation of renal fibrosis by proteasome inhibition in rat obstructive nephropathy: possible role of nuclear factor kappaB. International Journal of Molecular Medicine 2003 12 4 587 592 2-s2.0-2842593814
110. 2-treated human renal proximal tubular cells. Chemico-Biological Interactions 2010 185 3 253 262 2-s2.0-77952294468 10.1016/j.cbi.2010.03.019
111. Ashton-Chess J., Mai H. L., Jovanovic V., Renaudin K., Foucher Y., Giral M., Moreau A., Dugast E., Mengel M., Racapé M., Danger R., Usal C., Smit H., Guillet M., Gwinner W., Berre L. L., Dantal J., Soulillou J.-P., Brouard S., Immunoproteasome beta subunit 10 is increased in chronic antibody-mediated rejection. Kidney International 2010 77 10 880 890 2-s2.0-77951879580 10.1038/ki.2010.15
112. Lachmann N., Schütz M., Budde K., Schönemann C., Waiser J., Antihumoral rejection therapy by proteasome inhibitor bortezomib: a case series. Clinical Transplants 2009 351 358 2-s2.0-77954617224
113. Ho J., Rush D. N., Gibson I. W., Karpinski M., Storsley L., Bestland J., Stefura W., Hayglass K. T., Nickerson P. W., Early urinary CCL2 is associated with the later development of interstitial fibrosis and tubular atrophy in renal allografts. Transplantation 2010 90 4 394 400 2-s2.0-77955981759 10.1097/TP.0b013e3181e6424d
114. Kurian S. M., Heilman R., Mondala T. S., Nakorchevsky A., Hewel J. A., Campbell D., Robison E. H., Wang L., Lin W., Gaber L., Solez K., Shidban H., Mendez R., Schaffer R. L., Fischer J. S., Flechner S. M., Head S. R., Horvath S., Yates J. R. III, Marsh C. L., Salomon D. R., Biomarkers for early and late stage chronic allograft nephropathy by proteogenomic profiling of peripheral blood. PLoS ONE 2009 4 7 2-s2.0-67650564908 10.1371/journal.pone.0006212 e6212
115. Tetaz R., Trocmé C., Roustit M., Pinel N., Bayle F., Toussaint B., Zaoui P., Predictive diagnostic of chronic allograft dysfunction using urinary proteomics analysis. Annals of Transplantation 2012 17 3 52 60 2-s2.0-84868706332
116. Scherer A., Krause A., Walker J. R., Korn A., Niese D., Raulf F., Early prognosis of the development of renal chronic allograft rejection by gene expression profiling of human protocol biopsies. Transplantation 2003 75 8 1323 1330 2-s2.0-0242432341 10.1097/01.TP.0000068481.98801.10 (Pubitemid 36513042)
117. Scherer A., Gwinner W., Mengel M., Kirsch T., Raulf F., Szustakowski J. D., Hartmann N., Staedtler F., Engel G., Klupp J., Korn A., Kehren J., Haller H., Transcriptome changes in renal allograft protocol biopsies at 3 months precede the onset of interstitial fibrosistubular atrophy (IFTA) at 6 months. Nephrology Dialysis Transplantation 2009 24 8 2567 2575 2-s2.0-67651083506 10.1093/ndt/gfp183
118. Einecke G., Reeve J., Sis B., Mengel M., Hidalgo L., Famulski K. S., Matas A., Kasiske B., Kaplan B., Halloran P. F., A molecular classifier for predicting future graft loss in late kidney transplant biopsies. Journal of Clinical Investigation 2010 120 6 1862 1872 2-s2.0-77953223365 10.1172/JCI41789
119. Oetting W. S., Guan W., Schladt D. P., Wildebush W. A., Becker J., Thyagarajan B., Jacobson P. A., Matas A. J., Israni A. K., Telomere length of recipients and living kidney donors and chronic graft dysfunction in kidney transplants. Transplantation 2014 97 3 325 329
120. Maluf D. G., Dumur C. I., Suh J. L., Lee J. K., Cathro H. P., King A. L., Gallon L., Brayman K. L., Mas V. R., Evaluation of molecular profiles in calcineurin inhibitor toxicity post-kidney transplant: input to chronic allograft dysfunction. American Journal of Transplantation 2014 14 5 1152 1163
121. Walker J. K., Alloway R. R., Roy-Chaudhury P., Mogilishetty G., Cardi M. A., Weimert N. A., Rike A. H., First M. R., Woodle E. S., A prospective trial of a steroid-free/calcineurin inhibitor minimization regimen in human leukocyte
122. Fadili W., Habib Allah M., Laouad I., Chronic renal allograft dysfunction: risk factors, immunology and prevention. Arab Journal of Nephrology and Transplantation 2013 6 1 45 50 2-s2.0-84879153746
123. Schena F. P., Pascoe M. D., Alberu J., Del Carmen Rial M., Oberbauer R., Brennan D. C., Campistol J. M., Racusen L., Polinsky M. S., Goldberg-Alberts R., Li H., Scarola J., Neylan J. F., Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. Transplantation 2009 87 2 233 242 2-s2.0-59649126728 10.1097/TP.0b013e3181927a41
124. Luo L., Sun Z., Luo G., Rapamycin is less fibrogenic than Cyclosporin A as demonstrated in a rat model of chronic allograft nephropathy. Journal of Surgical Research 2013 179 1 E255 E263 2-s2.0-84870681560 10.1016/j.jss.2012.02. 059
125. Böhmig G. A., Regele H., Hörl W. H., Protocol biopsies after kidney transplantation. Transplant International 2005 18 2 131 139 2-s2.0-20444457078 10.1111/j.1432-2277.2004.00020.x (Pubitemid 41743302)
126. Paul L. C., New insights in chronic allograft rejection. Current Opinion in Urology 2002 12 2 89 93 2-s2.0-0036176834 10.1097/00042307-200203000-00002 (Pubitemid 34165508)
127. Shrestha B. M., Haylor J. L., Factors influencing long-term outcomes following renal transplantation: a review. Journal of the Nepal Medical Association 2007 46 167 136 142 2-s2.0-42249109398 (Pubitemid 351547193)
128. Khan H., Mubarak M., Aziz T., Ahmed E., Fazal Akhter S., Kazi J., Aa Naqvi S., Ah Rizvi S., Prevalence and risk factors for early chronic allograft nephropathy in a live related renal transplant program. Journal of Nephropathology 2014 3 2 69 79